This review discusses the clinical experience with intravenous ferric carboxymaltose (FCM) for treating iron deficiency anemia (IDA) in adults intolerant to or unresponsive to oral iron, or with nondialysis-dependent chronic kidney disease. FCM allows administration of up to 750 mg per dose (totaling 1500 mg over two doses), delivered over
